MAGAZINE

Acta Diabetologica

Diabetic retinopathy screening in urban primary care setting with a handheld smartphone‐based retinal camera

AUTHORS & DATE

Márcia Silva Queiroz; Jacira Xavier de Carvalho; Silvia Ferreira Bortoto; Mozania Reis de Matos; Cristiane das Graças Dias Cavalcante; Elenilda Almeida Silva Andrade; Maria Lúcia Correa-Giannella; Fernando Korn Malerbi.
04/08/2020

Abstract

Background

To evaluate diabetic retinopathy (DR) screening with a portable handheld smartphone-based retinal camera and telemedicine in an urban primary healthcare setting and to evaluate the learning curve for image acquisition, performed by healthcare personnel without previous experience in retinal imaging.

Methods

This was a prospective study that enrolled patients with type 2 diabetes mellitus (T2DM) followed at a primary healthcare unit in São Paulo, Brazil. After a brief training in image acquisition, there was further continuous feedback given by a retina specialist during the remote image reading process. Each patient underwent two fundus and one anterior ocular segment images per eye, after mydriasis. Patients were classified according to the need of referral.

Results

A total of 627 adult individuals with T2DM underwent retinal evaluation. The population was composed by 63.2% female individuals, age median of 66 years, diabetes duration 10.7±8.2 years and HbA1c 7.7±1.9% (61+20.8 mmol/mol). The most prevalent associated comorbidities were arterial hypertension (80.3%) and dyslipidemia (50.2%). Referral decision was possible in 81.2% patients. Most patients had absent or non-referable DR; the main ocular media opacity detected was cataract. After the 7th day of image acquisition, the daily rate of patients whose images allowed clinical decision was maintained above 80%. A higher HbA1c was associated with referable DR.

Conclusion

A low-cost DR screening strategy with a handheld device and telemedicine is feasible and has the potential to increase coverage of DR screening in underserved areas; the possibility of mobile units is relevant for DR screening in the context of COVID-19 pandemic.

Icon Button Request A QuoteRequest a Quote

Fechar

Ico Back

Later

Request a quote

Fill out the form below and we will contact you shortly.

    Ico Form Success

    Request a Quote

    Our team will contact you shortly.

    Close

    …complete suas informações

      By clicking the Complete button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
      Ico Back

      Depois

      Ico Form Success

      Obrigado por completar suas informações

      FECHAR

      Ico Back

      Depois

      Solicite e comece SEU TEST DRIVE

      Por favor, preencha o formulário abaixo que entraremos em contato.

        x

        Solicitar Orçamento

        Ao clicar em Solicitar, concordo com a Política de Privacidade e os Termos de Uso, permito que a Phelcom me contate e reconheço que o Eyer é um dispositivo médico (Anvisa classe II) exigindo a supervisão de um profissional com CRM para uso e interpretação das imagens.
        Ico Form Success

        Obrigado!

        Nosso time comercial logo entrará em contato para finalizar o processo.

        FECHAR

        Ico Back

        Later

        Request more information

        Please fill out the form below and we will contact you.

          x

          Request EyerMaps

          By clicking the Request button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
          Ico Form Success

          Thank you!

          Our commercial team will contact you shortly to finalize the process.Our commercial team will contact you shortly to finalize the process.
          CLOSE